医疗诊断公司Veracyte Inc（VCYT）周四盘中股价大涨8.47%，引发投资者关注。这一显著涨幅主要源于公司发布的强劲第二季度财报以及上调的全年业绩指引。
根据公司最新公布的财务报告，Veracyte第二季度总营收达到1.302亿美元，同比增长14%，超出分析师预期的1.207亿美元。其中，测试收入同比增长14%至1.223亿美元，主要由公司的Decipher Prostate和Afirma测试业务推动。尽管产品收入略有下滑，但生物制药及其他收入增长21%，达到430万美元。
更引人注目的是，Veracyte上调了2025年全年业绩指引。公司预计全年测试收入将达到4.77亿至4.83亿美元，同比增长14%至15%。同时，公司首次发布2025年全年总营收指引，预计为4.96亿至5.04亿美元，显示11%至13%的同比增长。此外，公司还将2025年调整后EBITDA占营收比例的指引从此前的22.5%上调至23.5%。这些积极的财务指标和乐观的业绩展望无疑增强了投资者对Veracyte未来增长潜力的信心，推动了股价的大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.